Servatus appoints Hugh Alsop as Non-Executive Director and expands clinical programs team with Dr. Jessica Allegretti
Sunshine Coast, Australia – 3 March 2020.
Servatus Ltd (Servatus) is pleased to announce two key appointments as it continues to execute on its strategy to build a leading biopharmaceutical company in Australia.
Firstly, to further strengthen our development and commercialisation skills, Hugh Alsop has been appointed as a non-executive director. Hugh brings significant expertise as Servatus continues to advance its development programs and build its biopharmaceutical production capability. Secondly, Dr. Jessica Allegretti, an internationally recognised gastroenterologist and microbiome expert based at Harvard University, has been appointed as the principal investigator for Servatus’ upcoming clinical trials in ulcerative colitis, a chronic Inflammatory Bowel Disease (IBD). Dr Allegretti will also be a key research and clinical adviser for the company, as it aims to deliver first line and adjunct treatments for select autoimmune, gastrointestinal and dermatological conditions.
Mr. Alsop brings over 22 years of experience as a biotech executive to Servatus, with his deep understanding of drug development and pharmaceutical commercialisation making him a strong addition to the board. Hugh currently holds the role of Chief Executive Officer for Kinoxis Therapeutics, a private Australian biotech company.
“Hugh has a strong track record in growing companies the pharmaceutical and biotechnology industries and Servatus plans to leverage his experience as we move forward with two major clinical studies in 2020, and complete construction and commissioning of our joint venture facility on the Sunshine Coast,” said Servatus CEO and Executive Director Dr. Wayne Finlayson.
The appointment of Dr. Allegretti will add significant clinical, IBD and microbiome research experience to the Servatus team. She currently serves as Director of Clinical Trials at Brigham and Women’s Hospital Crohn’s and Colitis Centre. In addition to her clinical responsibilities and caring for patients, Dr. Allegretti is the Director of the Fecal Microbiota Transplant Program and an attending Gastroenterologist at Brigham and Women’s Hospital (a Harvard Medical School teaching hospital). Dr. Allegretti graduated from Cornell University in Ithaca, New York, and the Miller School of Medicine at the University of Miami in Miami, Florida. She was trained in internal medicine at Massachusetts General Hospital and completed her gastroenterology fellowship training at Brigham and Women’s Hospital. She later went on to receive a Master of Public Health from the Harvard School of Public Health.
Servatus will work with Dr. Allegretti in the design of its upcoming clinical trial in ulcerative colitis, using the highly successful preclinical results with Charles River Laboratory as the platform for the next phase of research into developing biotherapeutic treatments for inflammatory bowel disease (IBD).
“Dr. Allegretti’s impressive experience in patient care and clinical research lends considerable perspective to the design of our clinical trial,” said Dr. Finlayson. “She has already made significant contributions to the gastroenterology field and her leadership in our clinical program will set the pace as we accelerate our biotherapeutic-based drug development programs.”
“The preclinical results that Servatus have achieved are very promising in developing an alternative microbiome-based therapy for IBD patients, and I’m eager to begin work alongside its scientists for this next set of clinical trials,” said Dr. Allegretti.
“Servatus has already accomplished a tremendous amount of work in establishing the foundations for its research,” said Mr. Alsop. “I’m excited to be a part of the team as we explore the developmental opportunities alongside Dr. Allegretti.”